Table 1.
Clinical Characteristics of patients with BCMA-CD38 CAR-T at baseline
| NO. | Age | Months of MM | Stage (ISS) | Subtype | EM | Cytogenetic abnormalities | Prior treatments | MRD (%) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Prior lines | PI | IMID | ASCT | ||||||||
| 1 | 62 | 6 | III | κ | No | 1q21 (9.0%) | 2 | BTZ | No | 6.96 | |
| 2 | 60 | 60 | III | IgA-λ | No | 1q21 (14.0%), RB1 (13.0%), D13S319 (13.0%) | 3 | BTZ | Thal, Lenal, Pomal | Yes | 3.68 |
| 3 | 50 | 18 | I | IgG-κ | No | 1q21 (31%), Del17p (13%) | 2 | BTZ | Yes | 8.80 | |
| 4 | 78 | 72 | III | IgA-λ | Yes | 1q21 (26.0%), Del17p (20.0%) | 3 | BTZ | Thal, Lenal | No | 13.50 |
| 5 | 70 | 66 | I | κ | No | Del17p (24.0%) | 3 | BTZ |
Lenal Thal |
No | 9.34 |
| 6 | 66 | 14 | III | IgG-λ | Yes | 1q21 (12%) | 3 | BTZ | Lenal | No | 32.21 |
| 7 | 57 | 46 | III | λ | No | No | 3 | BTZ, | Thal | No | 4.26 |
| 8 | 57 | 33 | III | λ | Yes | No | 3 | BTZ | Thal | No | 3.22 |
| 9 | 64 | 43 | III | IgG-κ | No | No | 3 | BTZ | Thal, Lenal | No | 0.95 |
| 10 | 55 | 10 | III | IgA-κ | No | No | 2 | BTZ | No | 4.31 | |
| 11 | 74 | 4 | III | IgA-κ | Yes | No | 2 | BTZ | No | 33.00 | |
| 12 | 63 | 42 | III | IgG-κ | Yes | 1q21 (62.0%) | 2 | BTZ | No | 5.46 | |
| 13 | 57 | 5 | III | IgA-λ | Yes | 1q21 (24.0%) | 2 | BTZ | Thal | No | 21.04 |
| 14 | 53 | 39 | II | IgG-λ | Yes | 1q21 (27.0%) | 3 | BTZ | Thal, Lenal Pomal | No | 2.92 |
| 15 | 48 | 24 | III | IgG-κ | Yes | 1q21 (11.2%) | 3 | BTZ | Yes | 5.03 | |
| 16 | 55 | 7 | IIII | IgA-κ | No | 1q21 (45.0%) | 3 | BTZ | No | 6.04 | |
ISS International stage system, EM Extramedullary lesions, PI Proteasome inhibitor, IMID immunomodulatory agents, ASCT Autologous hematopoietic stem cell transplantation, BTZ Bortezomib, THAL Thalidomide, Lenal Lenalidomide, Pomal Pomalidomide, MRD Minimal residual disease